391209-97-5

Basic information

• Product Name: BenzaMide, N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)aMino]-
• Synonyms: BenzaMide, N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)aMino]-;N-(2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide
• CAS NO: 391209-97-5
• Molecular Formula: C16H14F3IN2O4
• Molecular Weight: 482.1930396
• Mol File: 391209-97-5.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Density: 1.817±0.06 g/cm3(Predicted)
• PKA: 13.45±0.20(Predicted)
• CAS DataBase Reference: BenzaMide, N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)aMino]-(CAS DataBase Reference)
• NIST Chemistry Reference: BenzaMide, N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)aMino]-(391209-97-5)
• EPA Substance Registry System: BenzaMide, N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)aMino]-(391209-97-5)

Safety Data

• Hazardous Substances Data: 391209-97-5(Hazardous Substances Data)

Upstream product

• 391211-97-5 3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzoic acid 
• 120564-14-9 (4R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxyamine 
• 391212-52-5 N-{[(R)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy}-3,4-difluoro-2-[(2-fluoro-4-iodo-phenyl)amino]benzamide 
• 120564-14-9 (S)-O-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)hydroxylamine 
• 61079-72-9 2,3,4,-trifluorobenzoic acid 
• 29632-74-4 2-fluro-4-iodoaniline 
• 278610-42-7 5-chloro-2-(2-chloro-4-iodo-phenylamino)-3,4-difluoro-benzoic acid 

Downstream Products

• 1596369-19-5 (S)-4-(3-((3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamido)oxy)-2-hydroxypropoxy)-4-oxobutanoic acid 
• 1596369-20-8 (S)-3-((3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamido)oxy)-2-hydroxypropyl (2,5-dioxopyrrolidin-1-yl) succinate 

Relevant articles and documents

Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof

The present disclosure relates to: a) a crystalline composition of essentially pure Form IV of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide; b) pharmaceutical compositions comprising the crystalline composition of essentially pure Form IV of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, a pharmaceutically acceptable carrier; and c) methods of treating a tumor, a cancer, or a Rasopathy disorder by administering the crystalline composition of essentially pure Form IV of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide to a subject in need thereof.

5-SUBSTITUTED-2-PHENYLAMINO-BENZAMIDE AS MEK INHIBITOR

An objective of the present invention is to provide compounds that exhibit strong MEK-inhibiting activity and are stable in vivo and soluble in water, which can be used as preventive or therapeutic agents for proliferative diseases. The compounds of the present invention and pharmaceutically acceptable salts thereof are represented by the following formula (1): [where R1, R2, R3, R4, and X are the same as defined in the present patent application].

Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide

This invention provides a novel polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, as well a pharmaceutical compositions and therapeutic methods utilizing the polymorphic form.